Kala Bio (FRA:27F) Accounts Payable: €0.90 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:27F Kala Bio Inc FRA:27F
18 GF Score
Price €3.40
! 2 Warning Signs
View Full Analysis

What is Kala Bio Accounts Payable?

Kala Bio FRA:27F 18 Accounts Payable is €0.90 Mil as of Mar. 2026. GuruFocus rates FRA:27F with a GF Score™ of 18/100. The stock has 2 warning signs investors should review.

Kala Bio's Accounts Payable for the quarter that ended in Mar. 2026 was €0.90 Mil.

Kala Bio's quarterly Accounts Payable increased from Sep. 2025 (€0.78 Mil) to Dec. 2025 (€0.84 Mil) and increased from Dec. 2025 (€0.84 Mil) to Mar. 2026 (€0.90 Mil).

Kala Bio's annual Accounts Payable declined from Dec. 2023 (€0.84 Mil) to Dec. 2024 (€0.60 Mil) but then increased from Dec. 2024 (€0.60 Mil) to Dec. 2025 (€0.84 Mil).

Kala Bio Accounts Payable Historical Data

* Premium members only.

The historical data trend for Kala Bio's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kala Bio Accounts Payable Chart

Kala Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.34 2.67 0.84 0.60 0.84

Kala Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 0.57 0.78 0.84 0.90
FRA:27F
18GF Score
Kala Bio Inc FRA:27F
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kala Bio Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €0.90 Mil mean?
Kala Bio (FRA:27F) has a Accounts Payable of €0.90 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Kala Bio and its competitors.
Is Kala Bio's Accounts Payable too high?
Kala Bio's current Accounts Payable is €0.90 Mil. Overall, Kala Bio has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Kala Bio's Accounts Payable compare to MGX and HYPD?
Kala Bio's Accounts Payable of €0.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Kala Bio and its competitors. Kala Bio's current Accounts Payable is €0.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kala Bio stock overvalued right now?
Kala Bio (FRA:27F) has a current Accounts Payable of €0.90 Mil. The current Accounts Payable is €0.90 Mil. Kala Bio's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Kala Bio (FRA:27F), the current Accounts Payable is €0.90 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kala Bio Business Description

Other Exchanges KALA:USA0JQ2:UK27F:Germany
Address 1167 Massachusetts Avenue, Arlington, MA, USA, 02476
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
18GF Score

Get the complete analysis for FRA:27F

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.40
Price